The pharmaceutical industry is one of the biggest industries in the world. The Ocugen stock is one that caught our eye from this industry. With total revenues of $1.3 trillion, this industry’s main source of income is developing, researching, and distributing medications.
Ocugen Inc (OCGN) is a new company that develops medications and therapies for blindness. But in recent times, Ocugen is also in the market for a Covid-19 vaccine. As such, there is quite a lot of interest in the company. We believe Ocugen to be a promising stock pick worth pursuing. Here is our analysis and forecast on the matter.
Ocugen Stock Price and Analysis
At the current time of writing, the Ocugen stock isn’t in the best of places. While the year-to-date performance shows a promising 164.82% increase, it’s been going downhill in the past six months. The Ocugen stock sits at $8.13. This price represents a downfall of more than half of its 52-week high performance. But the stock performed well between late October and early November. Since then, the Ocugen stock is on freefall.
But where there is fall, there is also opportunity. The October-November spike is linked to the news that Ocugen petitioned the FDA for phase 3 clinical trials for their Covid-19 vaccine. With multiple projects in its pipeline, the company doesn’t currently have any reliable source of revenue. Many are questioning the company’s ability to rack up consistent numbers amidst developing the vaccine.
But the question of successfully developing the vaccine isn’t the only concern for the company. The market for Covid-19 vaccines is a dog-eat-dog world. As Pfizer and Moderna are currently controlling the North American Covid-19 vaccine market, there are quite a lot of concerns if Ocugen can even breach the market in the foreseeable future.
But our analysts are bullish on the Ocugen stock. Although the company looks to seize quite a small market, successfully developing a vaccine is exactly what can propel the company’s stock to new heights. As more Americans distrust Pfizer and Moderna, this could present the ideal opportunity for Ocugen.
Ocugen Stock – The Vaccine And Projects In the Pipeline
Any success on the vaccine front will reflect positively on the stock market. But there is another problem on the horizon. Ocugen isn’t licensed to sell its vaccine worldwide. At the current time of writing, they can only do it in the US. But there’s doubt even in their own backyard. To successfully sell the vaccine, they need approval from the FDA. While there is little information on how the approval is going, any success in the US market will also reflect positively in Canada.
If the FDA is in charge of approving the vaccine in the US, it’s the Ministry Of Health in Canada. Given the close relationship of the two countries, any success on either front will ultimately reflect positively for Ocugen. But what about other projects in its pipeline?
Ocugen has two additional projects to rely on if the vaccine fails. Unfortunately, both projects are years away from clinical trials. All that the Ocugen stock hinges on is the clinical trials for the Covid-19 vaccine. If these clinical trials prove successful, then the Ocugen stock will ultimately benefit.
Ocugen Stock – Is It Worth?
Ocugen Inc is one of the riskier stock picks. But where there is risk there is also an opportunity for huge gains. If the Covid-19 vaccine is approved, the Ocugen stock price will skyrocket. Given the supposed 93% efficiency rating of the vaccine, investors are optimistic that Ocugen will be approved to sell. As such, the $8.13 Ocugen stock price is a cheap option to experiment with and potentially make huge profits.
Partner at Vega Capital Management - a private funds management company.
An experienced portfolio manager with 10+ years of proven and reputable track record in investment management and financial analysis. Currently, a partner at one of the fastest-growing private fund management companies in southeast Europe, Kiril has been tending to a loyal international base of client-investors and partners. When he is not crunching numbers and increasing his client’s wealth, he reminisces about his Michelin-star restaurant cheffing years and fondness of the culinary arts.